Strategic Funding Harbinger Health has secured substantial backing with a $290M funding round and a recent Series B, signaling strong investor confidence and potential for scaled partnerships and enterprise collaborations in multi-cancer detection solutions.

Clinical Validation Recent ASCO presentations and data showcasing RESOLVE's performance across multiple high-incidence cancers provide credible evidence to approach payers, health systems, and oncology clinics about adoption and reimbursement discussions.

Product Readiness Launch of RESOLVE with first commercial products anticipated in the second half of 2026 creates a near-term opportunity to target pilot programs, early adopters, and strategically aligned cancer centers seeking innovative blood-based diagnostics.

Clinical Data Capabilities Advances in cfDNA methylation models for lung cancer progression from a single blood draw highlight capabilities that can be cross-sold to institutions needing noninvasive monitoring tools, potentially expanding into companion diagnostics or longitudinal testing programs.

Strategic Leadership New CEO Ajit Singh joins as a Flagship Pioneering leader, signaling a strong mandate for corporate partnerships, co-development opportunities, and scaled market access strategies that you can align with in outreach to health systems and research networks.